Finance
Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program
Jan 15, 2021 | 2:09 AM GMT
A broad syndicate has funded NewAmsterdam with a $196 million (€160 million) series A round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm for dyslipidemia.
Forbion, Morningside Ventures and Ascendant BioCapital led the round, which will fund a
